Henry M Kuerer MD PhD, FACS
Breast, Surgical Oncology (Other than Breast)
Professor and Executive Director, MD Anderson Cancer Center
Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Kuerer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Henry Kuerer is a surgeon in Houston, TX and is and Executive Director affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree and PhD from the University of New York Medical Center College of Medicine and has been in practice 28 years. He specializes in breast and surgical oncology. He has over 500 publications and over 30,000 citings and has helped to train countless surgeons in the care of cancer patients.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Breast Surgical Oncology, 1997 - 1998
Icahn School of Medicine at Mount SinaiResidency, Surgery, 1992 - 1997
State University of New York Downstate Medical Center College of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1998 - Present
FL State Medical License 2021 - Present
TX State Medical License 1997 - 2026
American Board of Surgery Surgery
Clinical Trials
- Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy Start of enrollment: 2017 Jan 20
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial.Henry M Kuerer, Vicente Valero, Benjamin D Smith, Savitri Krishnamurthy, Emilia J Diego
JAMA Oncology. 2025-03-28 - 2 citationsNodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study.Giacomo Montagna, Alison Laws, Massimo Ferrucci, Mary M Mrdutt, Susie X Sun
Journal of Clinical Oncology. 2025-03-01 - Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy.Alycia So, Min Yi, Janine M Simons, Henry M Kuerer, Abigail Caudle
Annals of Surgical Oncology. 2025-02-01
Press Mentions
Breast Surgery Can Be Omitted After Neoadjuvant Systemic Therapy in Select PatientsApril 11th, 2025- MD Anderson Study Questions Need for Breast Cancer Surgery in Select PatientsApril 2nd, 2025
- Breast Cancer Surgery: MD Anderson Study Raises QuestionsApril 2nd, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
